Claims for Patent: 7,902,343

Summary for Patent: 7,902,343

Title:	Detection of microsatellite instability and its use in diagnosis of tumors
Abstract:	Methods and kits are disclosed for use in the analysis of microsatellite instability in genomic DNA. Methods and kits are also disclosed which can be used to detect microsatellite instability DNA present in biological materials, such as tumors. The methods and kits of the present invention can be used to detect or diagnose diseases associated with microsatellite instability, such as certain types of cancer.
Inventor(s):	Bacher; Jeffery W. (Madison, WI), Flanagan; Laura (Fort Atkinson, WI), Nassif; Nadine (Madison, WI)
Assignee:	Promega Corporation (Madison, WI)
Application Number:	12/109,775
Patent Claims:	1. A kit for detecting microsatellite instability in a human DNA sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising oligonucleotide primers for co-amplifying a set of at least three quasi monomorphic loci of the DNA sample. 2. The kit of claim 1, wherein the oligonucleotide primers are comprised within a single container. 3. The kit of claim 1, wherein the set of loci comprises at least one locus selected from the group consisting of MONO-11 and MONO-15. 4. The kit of claim 3, wherein the set of loci further comprises at least one locus selected from the group consisting of BAT-25 and BAT-26. 5. The kit of claim 4, wherein the set of loci comprises MONO-11 and BAT-25. 6. The kit of claim 4, wherein the set of loci comprises MONO-11 and BAT-26. 7. The kit of claim 4, wherein the set of loci comprises MONO-15 and BAT-25. 8. The kit of claim 4, wherein the set of loci comprises MONO-15 and BAT-26. 9. The kit of claim 4, wherein the set of loci comprises at least three loci selected from the group consisting of BAT-25, BAT-26, MONO-11, and MONO-15. 10. The kit of claim 9, wherein the set of loci comprises BAT-25, BAT-26, MONO-11, and MONO-15. 11. The kit of claim 1, wherein at least one of the oligonucleotide primers is selected from the group consisting of: SEQ ID NO:1 and SEQ ID NO:60 when the locus is BAT-25, SEQ ID NO:61 and SEQ ID NO:62 when the locus is BAT-26, SEQ ID NO:7 and SEQ ID NO:8 when the locus is MONO-15, and SEQ ID NO:5 and SEQ ID NO:6 when the locus is MONO-11. 12. The kit of claim 1, wherein at least one oligonucleotide primer for each of the at least three quasi monomorphic loci in the set is fluorescently labeled. 13. The kit of claim 1, wherein the kit further comprises a thermostable polymerase. 14. The kit of claim 1, wherein the kit further comprises a first DNA control from normal non-cancerous biological material, and a second DNA control from a mismatch repair deficient cell. 15. The kit of claim 1, wherein the detection of microsatellite instability is used in tumor prognosis. 16. The kit of claim 1, wherein the detection of microsatellite instability is used to assess familial tumor predisposition. 17. The kit of claim 1, wherein the detection of microsatellite instability is indicative of tumors of the gastrointestinal system or of the endometrium. 18. The kit of claim 15, wherein the detection of microsatellite instability is indicative of colorectal cancer. 19. A kit for amplifying a set of at least one quasi monomorphic locus for detecting microsatellite instability in a human DNA sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising primers for amplifying a set of at least one quasi monomorphic locus selected from the group consisting of MONO-11 and MONO-15. 20. The kit of claim 19, wherein the locus is MONO-11. 21. The kit of claim 19, wherein the locus is MONO-15. 22. The kit of claim 19, wherein the set comprises MONO-11 and MONO-15. 23. The kit of claim 19, wherein the set further comprises BAT-25 or BAT-26. 24. The kit of claim 19, wherein the set comprises MONO-11 and BAT-25. 25. The kit of claim 19, wherein the set comprises MONO-11 and BAT-26. 26. The kit of claim 19, wherein the set comprises MONO-15 and BAT-25. 27. The kit of claim 19, wherein the set comprises MONO-15 and BAT-26. 28. A kit for detecting microsatellite instability in a human DNA sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising primers for co-amplifying a set of loci comprising at least one tetranucleotide repeat locus selected from the group consisting of D1S547, D1S1677, D2S1790, D3S2432, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D9S2169, D10S1426, D10S2470, and D17S1294. 29. The kit of claim 28, wherein the set of loci comprises at least two tetranucleotide repeat loci selected from the group consisting of D1S547, D1S1677, D2S1790, D3S2432, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D9S2169, D10S1426, D10S2470, and D17S1294. 30. The kit of claim 28, wherein the set of loci comprises at least three tetranucleotide repeat loci selected from the group consisting of D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D9S2169, D10S1426, D10S2470, D12S391, and D17S1294. 31. The kit of claim 28, wherein the set of loci comprises D1S518, D3S2432, D7S1808, D7S3046, D7S3070, and D10S1426. 32. The kit of claim 28, wherein the set of loci further comprises at least one mononucleotide repeat locus. 33. The kit of claim 28, wherein the set of loci comprises at least five loci comprising: at least two mononucleotide repeat loci selected from the group consisting of BAT-25, BAT-26, MONO-11, and MONO-15; and at least three tetranucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51. 34. The kit of claim 31, wherein the primers comprise SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:17, and SEQ ID NO:59.

Details for Patent 7,902,343

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biosolutions Canada Inc.	BAT	botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine)	Solution	125462	03/22/2013		2020-09-15